Get informed when a big investor buys or sells
+ FollowOvervalued by 35.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.27 Million |
|---|---|
| Enterprise Value | $1.95 Million |
| Earnings per Share | $-7.19 |
| Beta | 1.49 |
| Outstanding Shares | 6,773,125 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | -0.63 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.4 |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 2.29%▲ 2.29% |
|---|---|
| Total Invested | $289,455 |
| Investors Holding | 10▲ 10.00% |
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...